Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACV1 for painful diabetic peripheral neuropathy or post-herpetic neuralgia
ACTRN12607000201471Phase 2Terminated
- Sponsor
- Metabolic Pharmaceuticals
- Start
- Apr 2007
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of alpha-Conotoxin VC 1.1 in diabetic polyneuropathy (DPN) and postherpetic neuralgia (PHN) (2 arms), sponsored by Metabolic Pharmaceuticals. Primary endpoints: Safety and tolerability of ACV1, Vital sign monitoring and 8 more. Started Apr 2007; status: terminated.
02
Drugs
alpha-Conotoxin VC 1.1
03
Conditions
diabetic polyneuropathy (DPN)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on ACTRN12607000201471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000201471.